Navigation Links
New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology
Date:10/26/2010

BEDMINSTER, N.J., Oct. 26 /PRNewswire/ -- Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company, announced today that an analysis of two pivotal safety and efficacy studies of CAMBIA™ (diclofenac potassium for oral solution) will be presented at the 4th World Congress on Controversies in Neurology Conference (CONy) in Barcelona, Spain.

The new analysis will be presented in a poster (#23) entitled, "Rapid and Sustained Improvement in Migraine Symptoms with a New Powdered Formulation of Diclofenac Potassium for Oral Solution: Results from 2 Randomized Controlled Clinical Trials," and will be presented on Saturday, October 30, 2010 from 7:30 - 8:30 CEST by Alan Rapoport, MD of the David Geffen School of Medicine at University of California, Los Angeles.

About CAMBIA

CAMBIA, a novel, water-soluble, buffered diclofenac potassium powder, is the only prescription non-steroidal anti-inflammatory drug (NSAID) available for the acute treatment of migraine.  Engineered using Dynamic Buffering Technology™ (DBT), a patented absorption-enhancing technology developed by APR Applied Pharma Research S.A., CAMBIA is specifically designed for fast, effective relief from the symptoms of migraine. CAMBIA enters the bloodstream quickly and readily achieves peak plasma concentrations, providing pain relief in fifteen minutes for some patients. For more information, please visit www.cambiarx.com.

About Nautilus Neurosciences, Inc.

Nautilus Neurosciences is a neurology-focused specialty pharmaceutical company committed to providing the health care community with medically relevant products and services that directly benefit those affected by neurologic disorders.  Nautilus is backed by Tailwind Capital and Galen Partners.  For more information, please visit www.nautilusneurosciences.com.

Indication

CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older. CAMBIA is not indicated for prophylactic therapy or for cluster headache.

Important Safety Information

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

NSAIDs, including CAMBIA, may increase the risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk may increase with duration of use or in patients with CV disease or risk factors for CV disease. CAMBIA is contraindicated for peri-operative pain in coronary artery bypass graft surgery. NSAIDs increase the risk of gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk.

Use the lowest effective dose for the shortest possible duration. Long-term administration of NSAIDs can result in serious and potentially fatal events, including CV thrombotic events or GI reactions.

CAMBIA is contraindicated in patients with hypersensitivity to diclofenac or other NSAIDs, and in patients with preexisting asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic-like reactions have been reported in such patients. Anaphylactic reactions may also occur in patients with the aspirin triad or in patients without prior exposure to CAMBIA. CAMBIA is contraindicated in patients with the aspirin triad. Discontinue immediately if an anaphylactic reaction occurs.

Renal papillary necrosis and other renal injury may occur with long-term use of NSAIDs. Use CAMBIA with caution in patients at risk, including the elderly, those taking diuretics or ACE inhibitors, those with renal impairment, heart failure, or liver impairment. CAMBIA is not recommended in patients with advanced renal disease.

Use caution when prescribing CAMBIA with drugs known to be hepatotoxic (eg, acetaminophen, certain antibiotics, antiepileptics). Warn patients to avoid acetaminophen containing products while taking CAMBIA. The liver metabolizes almost 100% of diclofenac, and there is insufficient information to support dosing recommendations in patients with hepatic insufficiency. Hepatic effects range from transaminase elevations to liver failure. Discontinue CAMBIA immediately if abnormal liver tests persist or worsen.

NSAIDs can lead to new onset or worsening of preexisting hypertension. Monitor blood pressure closely during therapy. Patients taking ACE inhibitors, thiazides, or loop diuretics may have impaired response to these therapies when taking NSAIDs. Note that fluid retention and edema have been observed in some patients taking NSAIDs. Use CAMBIA with caution in patients with fluid retention or heart failure.

Using CAMBIA with other NSAIDs (eg, aspirin) or with anticoagulants (eg, warfarin) is not advised due to increased risk of serious adverse events, such as GI bleeding. Use with caution in patients with a history of ulcers or GI bleeding. Anemia may occur in patients on NSAIDs. In patients on long-term therapy, check hemoglobin or hematocrit upon any sign or symptom of anemia or blood loss.

NSAIDs, including CAMBIA, can cause serious skin reactions including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which can be fatal. Discontinue use immediately if rash or other signs of local skin reaction occur.

CAMBIA can harm fetuses. Starting at 30 weeks' gestation, pregnant women should avoid CAMBIA and other NSAIDs as premature closure of the ductus arteriosus in the fetus may occur. Use with caution in nursing mothers as it is not known if diclofenac is excreted in human milk.

The most common adverse events in clinical trials with CAMBIA were nausea and dizziness.


'/>"/>
SOURCE Nautilus Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017 Oncternal ... therapies for both rare and common malignancies, today ... B financing. The company intends to use the ... and TK216, and to advance preclinical development of ... Cirmtuzumab is a first-in-class anti-ROR1 monoclonal antibody ...
(Date:2/22/2017)... R.I. , Feb. 22, 2017  CVS Pharmacy ... the removal of partially hydrogenated oils (PHO), the primary ... all its exclusive store brands food products. The retailer ... which are free from artificial trans fats. This comes a ... Drug Administration,s deadline of June 2018 for processed foods ...
(Date:2/22/2017)... , Colombie-Britannique, February 22, 2017 Des scanners sur ... vente en Europe , au Moyen-Orient et en Afrique  ... Clarius Mobile Health , ... Vancouver , au Canada , a annoncé ... des Scanners Échographiques Sans fil Clarius C3 et L7, destinés à être ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... ... A product of digesting a micronutrient found in soy may hold the key ... while others do not, a University of Pittsburgh Graduate School of Public Health-led study ... some types of “good” gut bacteria when they metabolize isoflavones (micronutrients found in dietary ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Super-Sod will ... and 26 event in Athens, Georgia. , A shift from Super-Sod’s simple Athens Home ... Georgia. , For the booth, grass seed plant manager Chris Roquemore constructed furniture from ...
(Date:2/22/2017)... ... ... BrightStar Care Charleston , a home care and medical staffing agency, ... Center on Aging’s Senior Expo on Thursday, March 23, 2017, at the Omar ... in our community. We are thrilled to participate in this event because we believe ...
(Date:2/22/2017)... ... February 22, 2017 , ... Apptricity® Corporation, a leading ... spend management, today announced that Keppel Corporation has selected Apptricity Travel and Expense ... , “We are excited to announce the partnership between Keppel and Apptricity for ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... five new hospital-grade power extension cords that meet the most current standards. , ... 2012 edition of the National Fire Protection Association (NFPA) 101 – Life Safety ...
Breaking Medicine News(10 mins):